Table 5.

Relationship Between Mitotane and Survival in Subset Analyses

Subgroup	All patients			Patients who did not receive chemotherapy
Subgroup	No mitotane, mo	Mitotane, mo	p Value	No mitotane, mo	Mitotane, mo	p Value
Recurrence-free survival
Stage
I^*	—	—	—	—	—	—
II	41.0	11.8	0.08	41.0	28.9	0.17
II	24.7	10.0	0.08	24.7	16.0	0.27
IV	7.6	7.4	0.80	8.1	5.1	0.87
T1^*	—	—	—	—	—	—
T2	40.4	28.9	0.33	41.0	28.9	0.15
T3	20.5	9.8	0.10^y	24.7	11.0	0.03^†
T4	8.1	8.4	0.84	3.1	6.0	0.79
N0	39.1	8.4	0.004^†	39.1	16.0	0.11
N1	7.9	13.0	0.48	7.9	13.0	0.80
M0	29.4	11.8	0.03^†	29.4	13.0	0.11
M1^*	7.6	7.4	0.33	—	—	—
No hormone secretion	34.1	17.2	0.25	34.1	MNR	0.91
Hormone secretion	22.1	7.4	0.07	24.7	5.1	0.01^†
R0	33.6	9.8	0.01^y	33.6	9.8	0.02^†
R1	13.0	9.8	0.64	23.4	6.0	0.13
No capsular rupture	33.6	9.8	0.002^†	33.6	9.8	0.01^†
Capsular rupture	5.2	4.7	0.81	5.2	4.7	0.81
Overall survival
Stage
I^*	—	—	—	—	—	—
II	207.4	86.3	0.26	207.4	86.3	0.26
III	65.5	38.2	0.11	65.5	38.2	0.32
IV	11.4	14.9	0.63	8.2	14.4	0.21
T1^*	—	—	—	—	—	—
T2	207.4	86.3	0.36	207.4	86.3	0.45
T3	50.4	22.3	0.06	50.4	38.2	0.40
T4	11.4	14.9	0.72	11.0	14.4	0.63
N0	MNR	26.9	0.09	MNR	33.2	0.24
N1	18.4	24.3	0.86	16.9	MNR	0.44
M0	76.1	38.2	0.16	65.5	60.7	0.50
M1	7.4	14.6	0.51	4.1	6.5	0.54
No hormone secretion	52.9	49.4	0.92	53.9	MNR	0.34
Hormone secretion	47.3	19.0	0.04^†	47.3	26.5	0.11
R0	96.3	38.2	0.02^†	36.3	23.1	0.20
R1	23.2	11.5	0.45	23.2	9.0	0.32
R2	11.0	24.3	0.60	11.0	10.1	0.77
No capsular rupture	76.1	33.2	0.02^y	65.5	60.7	0.32
Capsular rupture	41.3	14.5	0.30	41.3	9.4	0.50

No event in one or both groups.

^†

Significant.

MNR, median not reached; R0, microscopically negative margin; R1, microscopically positive margin; R2, grossly positive margin.